Suppr超能文献

接受新辅助化疗的晚期卵巢癌患者的身心困扰。

Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, United States of America.

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.

出版信息

Gynecol Oncol. 2024 Nov;190:230-235. doi: 10.1016/j.ygyno.2024.08.024. Epub 2024 Sep 5.

Abstract

OBJECTIVE

This study compares baseline clinical characteristics, physical function testing, and patient-reported outcomes for patients undergoing primary cytoreductive surgery versus neoadjuvant chemotherapy, with the goal of better understanding unique patient needs at diagnosis.

METHODS

Patients with suspected advanced stage (IIIC/IV) epithelial ovarian cancer undergoing either primary cytoreductive surgery or neoadjuvant chemotherapy were enrolled in a single-institution, non-randomized prospective behavioral intervention trial of prehabilitation. Baseline clinical characteristics were abstracted. Physical function was evaluated using the Short Physical Performance Battery, Fried Frailty Index, gait speed, and grip strength. Patient-reported outcomes were evaluated using Patient-Reported Outcomes Measurement Information System metrics and the Perceived Stress Scale.

RESULTS

There were no significant differences in demographics or clinical characteristics between cohorts at enrollment, with the exception of performance status, clinical stage, and albumin. While gait speed and grip strength were lower amongst neoadjuvant chemotherapy patients, there were no significant differences in physical function using the Short Physical Performance Battery and Fried Frailty Index. Patients in the neoadjuvant chemotherapy cohort reported decreased perception of physical function and increased fatigue on Patient-Reported Outcomes Measurement Information System metrics. A larger proportion of patients in the neoadjuvant cohort reported severe levels of emotional distress and anxiety, as well as greater perceived stress at diagnosis.

CONCLUSIONS

Our findings suggest that patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer present with increased psychosocial distress and decreased perception of physical function at diagnosis and may benefit most from early introduction of supportive care.

摘要

目的

本研究比较了接受初次细胞减灭术与新辅助化疗的患者的基线临床特征、体能测试和患者报告的结局,旨在更好地了解诊断时患者的独特需求。

方法

在一家机构内,我们对疑似晚期(IIIC/IV 期)上皮性卵巢癌患者进行了一项关于预康复的单中心、非随机前瞻性行为干预试验,纳入了接受初次细胞减灭术或新辅助化疗的患者。我们提取了基线临床特征。使用简短体能测试、Fried 衰弱指数、步速和握力评估体能。使用患者报告结局测量信息系统指标和感知压力量表评估患者报告的结局。

结果

在入组时,两组患者在人口统计学和临床特征方面没有显著差异,除了体能状态、临床分期和白蛋白。新辅助化疗患者的步速和握力较低,但使用简短体能测试和 Fried 衰弱指数评估的体能没有显著差异。新辅助化疗组患者报告的患者报告结局测量信息系统指标的身体功能感知和疲劳感下降。新辅助组中更多的患者报告在诊断时出现严重的情绪困扰和焦虑,以及更大的感知压力。

结论

我们的研究结果表明,接受新辅助化疗的晚期卵巢癌患者在诊断时存在更多的心理社会困扰和身体功能感知下降,可能最需要早期引入支持性护理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验